CN106619650A - 一种治疗慢性肾小球炎的复合制剂 - Google Patents
一种治疗慢性肾小球炎的复合制剂 Download PDFInfo
- Publication number
- CN106619650A CN106619650A CN201611172006.2A CN201611172006A CN106619650A CN 106619650 A CN106619650 A CN 106619650A CN 201611172006 A CN201611172006 A CN 201611172006A CN 106619650 A CN106619650 A CN 106619650A
- Authority
- CN
- China
- Prior art keywords
- parts
- compound formulation
- chronic
- didymin
- menthol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 44
- 230000001684 chronic effect Effects 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 206010018364 Glomerulonephritis Diseases 0.000 title claims abstract 5
- VQEONGKQWIFHMN-UHFFFAOYSA-N Nordihydrocapsaicin Chemical compound COC1=CC(CNC(=O)CCCCCC(C)C)=CC=C1O VQEONGKQWIFHMN-UHFFFAOYSA-N 0.000 claims abstract description 24
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 19
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 19
- RMCRQBAILCLJGU-HIBKWJPLSA-N Didymin Chemical compound C1=CC(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 RMCRQBAILCLJGU-HIBKWJPLSA-N 0.000 claims abstract description 19
- RMCRQBAILCLJGU-UHFFFAOYSA-N Neoponcirin Natural products C1=CC(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 RMCRQBAILCLJGU-UHFFFAOYSA-N 0.000 claims abstract description 19
- SOTDSZCPWKTPCI-UHFFFAOYSA-N didymin Natural products COc1ccc(cc1)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 SOTDSZCPWKTPCI-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229940041616 menthol Drugs 0.000 claims abstract description 19
- HAVJATCHLFRDHY-UHFFFAOYSA-N Harringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HAVJATCHLFRDHY-UHFFFAOYSA-N 0.000 claims abstract description 18
- LEQAKWQJCITZNK-AXHKHJLKSA-N N-[(7S)-1,2-dimethoxy-10-(methylthio)-9-oxo-3-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide Chemical compound C1([C@@H](NC(C)=O)CCC2=C3)=CC(=O)C(SC)=CC=C1C2=C(OC)C(OC)=C3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O LEQAKWQJCITZNK-AXHKHJLKSA-N 0.000 claims abstract description 18
- LCXREBMNASQAOC-UHFFFAOYSA-N Worenine Chemical compound C1=C2C(C)=C(C=3C(=CC=4OCOC=4C=3)CC3)[N+]3=CC2=CC2=C1OCO2 LCXREBMNASQAOC-UHFFFAOYSA-N 0.000 claims abstract description 18
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims abstract description 18
- 229960002079 calcium pantothenate Drugs 0.000 claims abstract description 18
- HAVJATCHLFRDHY-JZTSUELASA-N harringtonine Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@](O)(CCC(C)(C)O)CC(=O)OC)[C@@H]4C2=CC2=C1OCO2 HAVJATCHLFRDHY-JZTSUELASA-N 0.000 claims abstract description 18
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960000287 thiocolchicoside Drugs 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 13
- YOEWQQVKRJEPAE-UHFFFAOYSA-L succinylcholine chloride (anhydrous) Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C YOEWQQVKRJEPAE-UHFFFAOYSA-L 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 40
- 238000009472 formulation Methods 0.000 claims description 37
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 16
- 235000019743 Choline chloride Nutrition 0.000 claims description 16
- 229960003178 choline chloride Drugs 0.000 claims description 16
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 7
- 229940086735 succinate Drugs 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 claims 1
- 240000008384 Capsicum annuum var. annuum Species 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- XDVZNDLANFJOQR-UHFFFAOYSA-N Coptisine Natural products O=Cc1c2OCOc2ccc1C=C3/NCCc4cc5OCOc5cc34 XDVZNDLANFJOQR-UHFFFAOYSA-N 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- XYHOBCMEDLZUMP-UHFFFAOYSA-N coptisine Chemical compound C1=C2C=C(C3=C(C=C4OCOC4=C3)CC3)[N+]3=CC2=C2OCOC2=C1 XYHOBCMEDLZUMP-UHFFFAOYSA-N 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 230000007774 longterm Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000007246 mechanism Effects 0.000 abstract description 2
- DAXYUDFNWXHGBE-NRAMRBJXSA-N Corynoxine Chemical compound O=C1NC2=CC=CC=C2[C@]11CCN2C[C@@H](CC)[C@@H](\C(=C/OC)C(=O)OC)C[C@H]21 DAXYUDFNWXHGBE-NRAMRBJXSA-N 0.000 abstract 1
- DAXYUDFNWXHGBE-WMLLIFGASA-N Corynoxine Natural products O=C1NC2=CC=CC=C2[C@]11CCN2C[C@@H](CC)[C@@H](\C(=C\OC)C(=O)OC)C[C@H]21 DAXYUDFNWXHGBE-WMLLIFGASA-N 0.000 abstract 1
- 229940120904 succinylcholine chloride Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 11
- 210000002700 urine Anatomy 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 6
- 229960002504 capsaicin Drugs 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229910021642 ultra pure water Inorganic materials 0.000 description 6
- 239000012498 ultrapure water Substances 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 4
- 208000020832 chronic kidney disease Diseases 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 206010001580 Albuminuria Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000132 chronic toxicity testing Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 231100000852 glomerular disease Toxicity 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种治疗慢性肾小球炎的复合制剂，所述治疗慢性肾小球炎的复合制剂，按照重量份的主要原料为：三尖杉酯碱18‑30份、香风草甙5‑15份、柯诺辛8‑12份、降二氢辣椒碱5‑12份、硫秋水仙苷4‑8份、氯化琥珀胆碱2‑6份、薄荷醇2‑8份、泛酸钙7‑14份、甲基黄连碱5‑18份。本发明药物根据慢性肾小球炎的认识机理对原料成分进行严格挑选，从而达到全面康复的目的，具有起效快、作用稳定、携带服用方便、长期服用无毒副作用的特点。
Description
技术领域
本发明涉及一种医药制备领域，具体是一种治疗慢性肾小球炎的复合制剂。
背景技术
慢性肾小球肾炎(chronic glomerulonephritis)，简称为慢性肾炎，系指蛋白尿、血尿、高血压、水肿为基本临床表现，起病方式各有不同，病情迁延，病变缓慢进展，以致不同程度肾功能减退，最终发展为慢性肾衰竭的一组肾小球疾病。由于本组疾病的病理类型及病期不同，主要临床表现各不相同，疾病表现呈多样化。目前临床使用的治疗慢性肾小球肾炎的中成药分为两大类：一为单体成分如冬虫夏草菌丝制剂；另一类为中药复方如复方肾炎片等等。前一类主要对肾脏局部损伤起保护作用，无法针对慢性肾脏疾病患者的临床表现进行治疗；后一类对慢性肾脏病患者的临床表现有一定作用，但慢性肾脏病肾脏局部的病理改变多为活动性病变与静止性病变并存，活动性病变得不到控制，临床表现虽为慢性过程，而肾脏本身的病变将进行性进展直至发展到尿毒症。
发明内容
本发明的目的在于提供一种治疗慢性肾小球炎的复合制剂，以解决上述背景技术中提出的问题。
为实现上述目的，本发明提供如下技术方案：
一种治疗慢性肾小球炎的复合制剂，按照重量份的主要原料为：三尖杉酯碱18-30份、香风草甙5-15份、柯诺辛8-12份、降二氢辣椒碱5-12份、硫秋水仙苷4-8份、氯化琥珀胆碱2-6份、薄荷醇2-8份、泛酸钙7-14份、甲基黄连碱5-18份。
作为本发明进一步的方案：所述治疗慢性肾小球炎的复合制剂，按照重量份的主要原料为：三尖杉酯碱21-27份、香风草甙8-12份、柯诺辛9-11份、降二氢辣椒碱7-11份、硫秋水仙苷4-8份、氯化琥珀胆碱2-6份、薄荷醇2-8份、泛酸钙8-12份、甲基黄连碱9-14份。
作为本发明进一步的方案：所述治疗慢性肾小球炎的复合制剂，按照重量份的主要原料为：三尖杉酯碱25份、香风草甙10份、柯诺辛10份、降二氢辣椒碱9份、硫秋水仙苷6份、氯化琥珀胆碱4份、薄荷醇5份、泛酸钙10份、甲基黄连碱12份。
一种治疗慢性肾小球炎的复合制剂的制备方法，具体步骤为：
首先，在医药级洁净区内，按上述计量比称取三尖杉酯碱、香风草甙、柯诺辛、降二氢辣椒碱、硫秋水仙苷、氯化琥珀胆碱、薄荷醇、泛酸钙、甲基黄连碱，过筛，机械混匀后添加超纯水，放置制药混合机中，混合4-8min，控制RSD≤5％，混合后压片并低温干燥，温度控制在4-8℃，包装即得治疗慢性肾小球炎的复合制剂。
作为本发明进一步的方案：具体步骤中混合6min。
与现有技术相比，本发明的有益效果是：
本发明药物根据慢性肾小球炎的认识机理对原料成分进行严格挑选，从而达到全面康复的目的，具有起效快、作用稳定、携带服用方便、长期服用无毒副作用的特点。
具体实施方式
下面将结合本发明实施例，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
实施例1
一种治疗慢性肾小球炎的复合制剂，按照重量份的主要原料为：三尖杉酯碱18份、香风草甙5份、柯诺辛8份、降二氢辣椒碱5份、硫秋水仙苷4份、氯化琥珀胆碱2份、薄荷醇2份、泛酸钙7份、甲基黄连碱5份。
一种治疗慢性肾小球炎的复合制剂的制备方法，具体步骤为：
首先，在医药级洁净区内，按上述计量比称取三尖杉酯碱、香风草甙、柯诺辛、降二氢辣椒碱、硫秋水仙苷、氯化琥珀胆碱、薄荷醇、泛酸钙、甲基黄连碱，过筛，机械混匀后添加超纯水，放置制药混合机中，混合4min，控制RSD≤5％，混合后压片并低温干燥，温度控制在4℃，包装即得治疗慢性肾小球炎的复合制剂。
实施例2
一种治疗慢性肾小球炎的复合制剂，按照重量份的主要原料为：三尖杉酯碱21份、香风草甙8份、柯诺辛9份、降二氢辣椒碱7份、硫秋水仙苷4份、氯化琥珀胆碱2份、薄荷醇2份、泛酸钙8份、甲基黄连碱9份。
一种治疗慢性肾小球炎的复合制剂的制备方法，具体步骤为：
首先，在医药级洁净区内，按上述计量比称取三尖杉酯碱、香风草甙、柯诺辛、降二氢辣椒碱、硫秋水仙苷、氯化琥珀胆碱、薄荷醇、泛酸钙、甲基黄连碱，过筛，机械混匀后添加超纯水，放置制药混合机中，混合4min，控制RSD≤5％，混合后压片并低温干燥，温度控制在4℃，包装即得治疗慢性肾小球炎的复合制剂。
实施例3
一种治疗慢性肾小球炎的复合制剂，按照重量份的主要原料为：三尖杉酯碱25份、香风草甙10份、柯诺辛10份、降二氢辣椒碱9份、硫秋水仙苷6份、氯化琥珀胆碱4份、薄荷醇5份、泛酸钙10份、甲基黄连碱12份。
一种治疗慢性肾小球炎的复合制剂的制备方法，具体步骤为：
首先，在医药级洁净区内，按上述计量比称取三尖杉酯碱、香风草甙、柯诺辛、降二氢辣椒碱、硫秋水仙苷、氯化琥珀胆碱、薄荷醇、泛酸钙、甲基黄连碱，过筛，机械混匀后添加超纯水，放置制药混合机中，混合6min，控制RSD≤5％，混合后压片并低温干燥，温度控制在6℃，包装即得治疗慢性肾小球炎的复合制剂。
实施例4
一种治疗慢性肾小球炎的复合制剂，按照重量份的主要原料为：三尖杉酯碱27份、香风草甙12份、柯诺辛11份、降二氢辣椒碱11份、硫秋水仙苷8份、氯化琥珀胆碱6份、薄荷醇8份、泛酸钙12份、甲基黄连碱14份。
一种治疗慢性肾小球炎的复合制剂的制备方法，具体步骤为：
首先，在医药级洁净区内，按上述计量比称取三尖杉酯碱、香风草甙、柯诺辛、降二氢辣椒碱、硫秋水仙苷、氯化琥珀胆碱、薄荷醇、泛酸钙、甲基黄连碱，过筛，机械混匀后添加超纯水，放置制药混合机中，混合8min，控制RSD≤5％，混合后压片并低温干燥，温度控制在8℃，包装即得治疗慢性肾小球炎的复合制剂。
实施例5
一种治疗慢性肾小球炎的复合制剂，按照重量份的主要原料为：三尖杉酯碱30份、香风草甙15份、柯诺辛12份、降二氢辣椒碱12份、硫秋水仙苷8份、氯化琥珀胆碱6份、薄荷醇8份、泛酸钙14份、甲基黄连碱18份。
一种治疗慢性肾小球炎的复合制剂的制备方法，具体步骤为：
首先，在医药级洁净区内，按上述计量比称取三尖杉酯碱、香风草甙、柯诺辛、降二氢辣椒碱、硫秋水仙苷、氯化琥珀胆碱、薄荷醇、泛酸钙、甲基黄连碱，过筛，机械混匀后添加超纯水，放置制药混合机中，混合8min，控制RSD≤5％，混合后压片并低温干燥，温度控制在8℃，包装即得治疗慢性肾小球炎的复合制剂。
药理学试验
1、慢性毒性试验
以本发明实施例3制得的复合制剂为试验，采用灌胃给药方式，在24h内连续给药3次，每次间隔6h，每次给药500mg/kg药量，每天累积药物总量达1500mg药物/kg，相当于人临床用量的100倍。给药后7d内，小鼠活动、进食、排泄均正常，生长良好，毛色光亮，其平均体重均随实验时间的延长而增加。第8d处死后解剖每只小鼠，肉眼观察心、肝、脾、肺、肾、脑、胸腺、胃、肠等均未发现颜色及形态异常，未能测出半数致死量(LD50)。结果表明：本发明复合制剂无慢性毒性反应。
2、长期毒性试验
以本发明实施例3制得的复合制剂为试验，采用灌胃给药方式，将本发明复合制剂分为低剂量、中剂量、高剂量三组，各组的药物用量分别为150、300、450mg药物/kg/d，相当于临床剂量的10、20、30倍。灌胃给药24周后，本发明药物对动物的一般状况、血液学指标、血液生化指标均无明显的影响，系统解剖、脏器系数及组织病理学检查也未发现异常病理改变。停药2周也未见明显改变。结果表明：本发明复合制剂在长期毒性试验中，未发现明显毒性反应和延迟毒性反应。可见，本发明复合制剂无毒性反应，长期用药安全可靠。
3、临床试验
收治符合西医诊断标准的患者，共92例患者，男性43例，女性49例，平均年龄42.5岁，平均病程1.7年，尿蛋白量1.32±0.63g/d，血尿素氮7.64±1.22mmol/L，血肌酐168.41±51.32μmol/L。
西医诊断标准：(1)起病缓慢，病情迁延，时轻时重，肾功能逐步减退，血尿素氮、血肌酐轻度升高；(2)有不同程度的蛋白尿(尿蛋白定量>1g/24h)、血尿、水肿及高血压；(3)病程中可因呼吸道感染等原因诱发慢性发作，出现类似慢性肾炎的表现。
疗效判断标准：1.完全缓解：浮肿、腰痛完全消失，尿蛋白持续阴性，24小时尿蛋白定量持续小于0.3g，肾功能正常；2.基本缓解：浮肿与腰痛基本消失，尿蛋白持续减少50％以上，肾功能正常或基本正常(与正常值相差不超过15％)；3.有效：水肿与腰痛明显好转，24小时尿蛋白量持续减少25％～49％，肾功能正常或有改善；4.无效：临床表现现与实验室检查均无明显改善或反而加重者。
治疗效果：92例患者采用本发明实施例3制备的复合制剂进行治疗，每天服用15mg/kg，治疗30天后，尿蛋白量0.54±0.82g/d，血尿素氮7.04±1.32mmol/L，血肌酐121.65±69.29μmol/L，与治疗前有显著性差异；完全缓解45例，基本缓解21例，有效23例，无效3例，总有效率96.7％；且在整个治疗期间均未出现不良反应。
对于本领域技术人员而言，显然本发明不限于上述示范性实施例的细节，而且在不背离本发明的精神或基本特征的情况下，能够以其他的具体形式实现本发明。因此，无论从哪一点来看，均应将实施例看作是示范性的，而且是非限制性的，本发明的范围由所附权利要求而不是上述说明限定，因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。
此外，应当理解，虽然本说明书按照实施方式加以描述，但并非每个实施方式仅包含一个独立的技术方案，说明书的这种叙述方式仅仅是为清楚起见，本领域技术人员应当将说明书作为一个整体，各实施例中的技术方案也可以经适当组合，形成本领域技术人员可以理解的其他实施方式。
Claims (5)
1.一种治疗慢性肾小球炎的复合制剂，其特征在于，按照重量份的主要原料为：三尖杉酯碱18-30份、香风草甙5-15份、柯诺辛8-12份、降二氢辣椒碱5-12份、硫秋水仙苷4-8份、氯化琥珀胆碱2-6份、薄荷醇2-8份、泛酸钙7-14份、甲基黄连碱5-18份。
2.根据权利要求1所述的治疗慢性肾小球炎的复合制剂，其特征在于，所述治疗慢性肾小球炎的复合制剂，按照重量份的主要原料为：三尖杉酯碱21-27份、香风草甙8-12份、柯诺辛9-11份、降二氢辣椒碱7-11份、硫秋水仙苷4-8份、氯化琥珀胆碱2-6份、薄荷醇2-8份、泛酸钙8-12份、甲基黄连碱9-14份。
3.根据权利要求1或2所述的治疗慢性肾小球炎的复合制剂，其特征在于，所述治疗慢性肾小球炎的复合制剂，按照重量份的主要原料为：三尖杉酯碱25份、香风草甙10份、柯诺辛10份、降二氢辣椒碱9份、硫秋水仙苷6份、氯化琥珀胆碱4份、薄荷醇5份、泛酸钙10份、甲基黄连碱12份。
4.一种如权利要求1-3任一所述的治疗慢性肾小球炎的复合制剂的制备方法，其特征在于，具体步骤为：
首先，在医药级洁净区内，按上述计量比称取三尖杉酯碱、香风草甙、柯诺辛、降二氢辣椒碱、硫秋水仙苷、氯化琥珀胆碱、薄荷醇、泛酸钙、甲基黄连碱，过筛，机械混匀后添加超纯水，放置制药混合机中，混合4-8min，控制RSD≤5％，混合后压片并低温干燥，温度控制在4-8℃，包装即得治疗慢性肾小球炎的复合制剂。
5.根据权利要求4所述的治疗慢性肾小球炎的复合制剂的制备方法，其特征在于，具体步骤中混合6min。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611172006.2A CN106619650A (zh) | 2016-12-17 | 2016-12-17 | 一种治疗慢性肾小球炎的复合制剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611172006.2A CN106619650A (zh) | 2016-12-17 | 2016-12-17 | 一种治疗慢性肾小球炎的复合制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106619650A true CN106619650A (zh) | 2017-05-10 |
Family
ID=58823166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611172006.2A Withdrawn CN106619650A (zh) | 2016-12-17 | 2016-12-17 | 一种治疗慢性肾小球炎的复合制剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106619650A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1127572A2 (en) * | 2000-02-25 | 2001-08-29 | Basf Aktiengesellschaft | Use of flavones for treating cycloxygenase-2 mediated diseases |
| CN101615222A (zh) * | 2008-06-23 | 2009-12-30 | 中国医学科学院放射医学研究所 | 一种基于中药有效成分群的中药组方设计技术 |
-
2016
- 2016-12-17 CN CN201611172006.2A patent/CN106619650A/zh not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1127572A2 (en) * | 2000-02-25 | 2001-08-29 | Basf Aktiengesellschaft | Use of flavones for treating cycloxygenase-2 mediated diseases |
| CN101615222A (zh) * | 2008-06-23 | 2009-12-30 | 中国医学科学院放射医学研究所 | 一种基于中药有效成分群的中药组方设计技术 |
Non-Patent Citations (8)
| Title |
|---|
| 俞雯雯等: "泛素化调控与中药抗炎", 《医学综述》 * |
| 傅志贤等: "香草酸受体调节剂", 《药学进展》 * |
| 刘慧琼等: "大叶钩藤中柯诺辛碱的含量测定", 《时珍国医国药》 * |
| 廖传德: "泛酸钙维生素E合并治疗结节性血管炎", 《武汉医学杂志》 * |
| 杨仁仪: "神经肌肉松弛剂在机械通气中的应用", 《中国实用儿科杂志》 * |
| 王勇: "《辨质辨病临床应用手册——中西医结合快速诊疗六十病》", 30 September 2014, 中医古籍出版社 * |
| 钟建庭等: "小剂量三尖杉酯碱治疗紫癜性肾炎", 《中国现代医学杂志》 * |
| 陈婷等: "芳香类药用植物抗炎镇痛活性成分及其作用机制研究进展", 《中草药》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2017101536A1 (zh) | 一种防治关节炎的药物组合物及其制备方法 | |
| CN108283643A (zh) | 一种噻嗪二酮类化合物在制备预防或治疗类风湿性关节炎的药物中的应用 | |
| CN102091141A (zh) | 一种治疗痛风的药物及其制备方法 | |
| CN105770850A (zh) | 一种辅助治疗骨关节疾病的保健品及其制备方法 | |
| CN106668600A (zh) | 一种治疗慢性肾小球炎的复合制剂 | |
| CN106619650A (zh) | 一种治疗慢性肾小球炎的复合制剂 | |
| CN106728049A (zh) | 一种治疗慢性肾小球炎的中西药复合制剂及其制备方法 | |
| WO1999016432A1 (fr) | Medicament pour le traitement de la nephropathie diabetique | |
| CN106728145A (zh) | 一种治疗急性腹泻的中西药组合物及其制备方法 | |
| CN108578473A (zh) | 一种治疗胃痛的药物及其制备方法 | |
| CN106822133A (zh) | 一种治疗急性腹泻的西药组合物 | |
| CN106511440A (zh) | 一种治疗慢性痢疾的复合中西药组合及其制备方法 | |
| CN106727632A (zh) | 一种治疗急性肾小球炎的复合制剂 | |
| CN107929669A (zh) | 一种治疗银屑病的中药组合物及其制备方法 | |
| CN106668048A (zh) | 一种治疗弥散性肺纤维化的西药 | |
| CN106822239A (zh) | 一种治疗上呼吸道感染的中西药组合物及其制备方法 | |
| CN106581024A (zh) | 一种治疗高血脂的西药组合物 | |
| CN106692264A (zh) | 一种治疗急性肾小球炎的复合制剂 | |
| CN106727642A (zh) | 一种儿童用退烧药 | |
| CN106581031A (zh) | 一种治疗百日咳的复合西药 | |
| CN106727883A (zh) | 一种治疗急性肾小球炎的中西药复合制剂及其制备方法 | |
| CN106581038A (zh) | 一种治疗哮喘病的药物 | |
| CN106668000A (zh) | 一种治疗喘息样支气管炎的药物 | |
| CN106727508A (zh) | 一种治疗慢性痢疾的复合药物 | |
| CN106581025A (zh) | 一种治疗慢性痢疾的复合西药 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170510 |